肿瘤细胞治疗研究
英文原题：CAR-T cell therapy: potential for paediatric brain tumours-an update.
中枢神经系统（CNS）肿瘤是儿童最致命的癌症，目前治疗方案有限。
中枢神经系统（CNS）肿瘤是儿童最致命的癌症，目前治疗选择有限。嵌合抗原受体（CAR）-T 细胞疗法已成为一种创新方法，并得到令人鼓舞的临床结果支持。目前使用 CAR-T 细胞治疗儿童 CNS 癌症的临床试验在诸多变量上存在差异，包括 CAR-T 细胞的递送途径、是否进行淋巴清除、所确定的靶抗原以及 CAR 工程化特征。考虑这些领域的早期经验是开发更有效治疗选择的关键一步，尤其是鉴于免疫抑制性肿瘤微环境、各种毒性、CAR-T 细胞耗竭以及肿瘤抗原异质性所带来的挑战。总之，尽管仍需持续创新，但 CAR-T 细胞对于这一类毁灭性疾病而言代表了一种有前景的治疗方法。
Central nervous system (CNS) tumours are the deadliest cancer for children and currently present limited treatment options. Chimeric antigen receptor (CAR)-T cell therapies have emerged as an innovative approach supported by encouraging clinical results. Current clinical trials using CAR-T cells in the treatment of paediatric CNS cancers differ in a number of variables, including the CAR-T cell route of delivery, presence of lymphodepletion, identified target antigen, and CAR engineering features. Considering early learnings across these areas is an essential step to developing more effective treatment options, especially given the challenges of immunosuppressive tumour microenvironments, various toxicities, CAR-T cell exhaustion, and tumour antigen heterogeneity. In sum, while there is a need for continued innovation, CAR-T cells represent a promising treatment approach for this devastating category of diseases.
MEMBER ACCOUNT
登录成功会直接打开下一页。
